Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. ABBV
8. DFTX
9. USO
10. IBM

Go back to Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

Leap Therapeutics (LPTX) PT Raised to $5 at Piper Sandler Following Positive Data at ESMO

September 20, 2021 8:34 AM EDT

Piper Sandler analyst Tyler Van Buren raised the price target on Leap Therapeutics (NASDAQ: LPTX) to $5.00 (from $4.00) while maintaining an Overweight rating following data presented at ESMO from the DisTinGuish study in 1st-line G/GEJ cancer that featured two KOLs.

The analyst... More

Leap Therapeutics (LPTX) Climbs 58%

September 16, 2021 6:08 AM EDT

Leap Therapeutics (NASDAQ: LPTX) Climbs 58%

Earlier Leap Therapeutics (LPTX) Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab... More